References – Probudur™
Prolonged analgesia from Bupisome and Bupigel formulations: From design and fabrication to improved stability
Rivka Cohen, Hiba Kanaan, Gilbert J. Grant, Yechezkel Barenholz
Journal of Controlled Release
Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label.
References – Envelta™
Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice
Keith M. Olson, Todd M. Hillhouse, Gwendolyn E. Burgess, Joshua L. West, James E. Hallahan, Isaac J. Dripps, Allison G. Ladetto, Kenner C. Rice, Emily M. Jutkiewicz and John R. Traynor
Journal of Pharmacology and Experimental Therapeutics
“Here we show that the opioid diprenorphine, a compound with mu-opioid receptor antagonist activity and delta- and kappa-opioid receptor partial agonist activities, has rapid onset antidepressant-like activity in animal models.“
Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia
Lisa Godfrey, Antonio Iannitelli, Natalie L. Garrettc, Julian Moger, Ian Imbert, Tamara King, Frank Porreca, Ramesh Soundararajan, Aikaterini Lalats, Andreas G. Schätzlein, Ijeoma F. Uchegbu
Journal of Controlled Release
There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals.
We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids.
Currently, enkephalins are limited in their therapeutic potential by their pharmacokinetic profiles due to their inability to cross the blood-brain barrier to reach opioid receptors located in the central nervous system.
Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain
Nestor N. Jimenez-Vargas, Jing Gong, Matthew J. Wisdom, Dane D. Jensen, Rocco Latorre, Alan Hegron, Shavonne Teng, Jesse J. DiCello, Pradeep Rajasekhar, Nicholas A. Veldhuis, Simona E. Carbone, Yang Yu, Cintya Lopez-Lopez, Josue Jaramillo-Polanco, Meritxell Canals, David E. Reed, Alan E. Lomax, Brian L. Schmidt, View ORCID ProfileKam W. Leong, Stephen J. Vanner, Michelle L. Halls, Nigel W. Bunnett, and Daniel P. Poole
National Academy of Sciences
Post Cancer Pain
References – NobrXiol™
References – AnQlar™
SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
Krzysztof Pyrć, Aleksandra Milewska, Emilia Barreto Duran, Paweł Botwina, Agnieszka Dabrowska, Malwina Jedrysik, Malgorzata Benedyk, Rui Lopes, Alejandro Arenas-Pinto, Moutaz Badr, Ryan Mellor, Tammy L. Kalber, Delmiro Fernandez-Reyes, Andreas G. Schätzlein & Ijeoma F. Uchegbu
“We hypothesise that preventing viral entry into mammalian nasal epithelial cells may be one way to limit the spread of COVID-19. Here we show that a positively charged polymer is able to reduce the infectivity of SARS-COV-2.”
SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
Krzysztof Pyrć, Aleksandra Milewska, Emilia Barreto Duran, Paweł Botwina, Rui Lopes, Alejandro Arenas-Pinto, Moutaz Badr, Ryan Mellor, Tammy L. Kalber, Delmiro Fernandes-Reyes, Andreas G. Schätzlein, Ijeoma F. Uchegbu
We hypothesise that preventing viral entry into mammalian nasal epithelial cells may be one way to limit the spread of COVID-19. We can show that the polymer GCPQ is able to reduce the infectivity of SARS-COV-2 and limit infectivity in human airway epithelial cells.
References – Epoladerm™
Knee Osteoarthritis: A Primer
Michelle J Lespasio, DNP, JD, ANP; Nicolas S Piuzzi, MD; M Elaine Husni, MD, MPH; George F Muschler, MD; AJ Guarino, PhD; Michael A Mont, MD
Osteoarthritis Research Society International (OARSI)
A synopsis of the current medical understanding of knee osteoarthritis. The prevalence, causes and associated risk factors, symptoms, diagnosis
and classification, and treatment options are described in detail.